Mapi initiated the Phase III study in October and is a 1,000 patient pivotal clinical study designed to support a New Drug Application (NDA) with the FDA. Mapi is also building capacity at its facility to supply GA-Depot for commercial sale, pending approval.
In the U.S., a study funded by the National MS Society estimates that nearly 1 million people are living with MS. Relapsing-remitting MS accounts for approximately 85% of initial MS diagnoses. According to recent market research, the global multiple sclerosis drugs market is anticipated to expand at a CAGR of 6.7%, and reach $39 billion by the end of 2026.